Nathalie Barbier

1.1k total citations
19 papers, 832 citations indexed

About

Nathalie Barbier is a scholar working on Dermatology, Immunology and Allergy and Physiology. According to data from OpenAlex, Nathalie Barbier has authored 19 papers receiving a total of 832 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Dermatology, 10 papers in Immunology and Allergy and 6 papers in Physiology. Recurrent topics in Nathalie Barbier's work include Dermatology and Skin Diseases (11 papers), Food Allergy and Anaphylaxis Research (8 papers) and Allergic Rhinitis and Sensitization (8 papers). Nathalie Barbier is often cited by papers focused on Dermatology and Skin Diseases (11 papers), Food Allergy and Anaphylaxis Research (8 papers) and Allergic Rhinitis and Sensitization (8 papers). Nathalie Barbier collaborates with scholars based in Switzerland, Germany and Canada. Nathalie Barbier's co-authors include C. Paul, Kim Papp, Y. De Prost, Regina Fölster‐Holst, Paul C. Potter, Jean‐Paul Ortonne, Roger J. Allen, Lawrence F. Eichenfield, Robert Cherill and Ann Bingham and has published in prestigious journals such as PEDIATRICS, Journal of Allergy and Clinical Immunology and Journal of the American Academy of Dermatology.

In The Last Decade

Nathalie Barbier

18 papers receiving 788 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Nathalie Barbier Switzerland 11 748 627 145 63 52 19 832
Eileen Jaracz United States 14 681 0.9× 537 0.9× 77 0.5× 41 0.7× 105 2.0× 16 756
May E. Venturanza United States 9 382 0.5× 302 0.5× 89 0.6× 95 1.5× 15 0.3× 33 453
Bridget Kaufman United States 6 373 0.5× 177 0.3× 77 0.5× 45 0.7× 25 0.5× 15 445
Murlidhar Rajagopalan India 11 452 0.6× 100 0.2× 49 0.3× 109 1.7× 84 1.6× 20 617
Robin Graham‐Brown United Kingdom 11 321 0.4× 164 0.3× 71 0.5× 25 0.4× 60 1.2× 26 495
Yuka Asai Canada 13 231 0.3× 309 0.5× 100 0.7× 18 0.3× 51 1.0× 43 579
José Carlos Armario Hita Spain 13 307 0.4× 149 0.2× 112 0.8× 78 1.2× 15 0.3× 55 405
Hany Elmaraghy United States 9 315 0.4× 118 0.2× 82 0.6× 66 1.0× 17 0.3× 30 419
Parbeer Grewal Canada 10 184 0.2× 93 0.1× 56 0.4× 38 0.6× 34 0.7× 22 263
Tuấn Anh Lê Japan 6 263 0.4× 199 0.3× 129 0.9× 35 0.6× 13 0.3× 13 341

Countries citing papers authored by Nathalie Barbier

Since Specialization
Citations

This map shows the geographic impact of Nathalie Barbier's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Nathalie Barbier with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Nathalie Barbier more than expected).

Fields of papers citing papers by Nathalie Barbier

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Nathalie Barbier. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Nathalie Barbier. The network helps show where Nathalie Barbier may publish in the future.

Co-authorship network of co-authors of Nathalie Barbier

This figure shows the co-authorship network connecting the top 25 collaborators of Nathalie Barbier. A scholar is included among the top collaborators of Nathalie Barbier based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Nathalie Barbier. Nathalie Barbier is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

19 of 19 papers shown
1.
Dyachkova, Yulia, Cornelia Dunger‐Baldauf, Nathalie Barbier, et al.. (2024). Do You Want to Stay Single? Considerations on Single‐Arm Trials in Drug Development and the Postregulatory Space. Pharmaceutical Statistics. 23(6). 1206–1217. 1 indexed citations
2.
Bérard, F., Sarbjit S. Saini, Marcus Maurer, et al.. (2024). Analysis of safety data of remibrutinib from completed phase 2 studies in inflammatory immune-mediated diseases. Revue française d'allergologie. 64. 103861–103861.
3.
Bernstein, Jonathan A., Ana M. Giménez‐Arnau, Marcus Maurer, et al.. (2023). Why a Complete Response Is the Treatment Aim in Chronic Spontaneous Urticaria. Journal of Clinical Medicine. 12(10). 3561–3561. 8 indexed citations
4.
Giménez‐Arnau, Ana M., Marcus Maurer, Jonathan A. Bernstein, et al.. (2022). Ligelizumab improves sleep interference and disease burden in patients with chronic spontaneous urticaria. Clinical and Translational Allergy. 12(2). e12121–e12121. 12 indexed citations
5.
Choi, YounJeong, Nathalie Barbier, Sabine Fürst‐Recktenwald, et al.. (2022). Analysis and reporting of pediatric growth and development assessment from clinical trials: overview and challenges. Journal of Biopharmaceutical Statistics. 33(6). 786–799. 3 indexed citations
6.
Metz, Martin, Jonathan A. Bernstein, Ana M. Giménez‐Arnau, et al.. (2022). Ligelizumab improves angioedema, disease severity and quality-of-life in patients with chronic spontaneous urticaria. World Allergy Organization Journal. 15(11). 100716–100716. 4 indexed citations
7.
8.
Bernstein, Jonine L., Marcus Maurer, A.M. Giménez-Arnau, et al.. (2020). P153 COMPLETE CONTROL OF URTICARIA SYMPTOMS WITH LIGELIZUMAB HELPS NORMALIZE QUALITY OF LIFE. Annals of Allergy Asthma & Immunology. 125(5). S22–S22. 1 indexed citations
9.
Barbier, Nathalie, et al.. (2017). Kinetics of CrPV and HCV IRES-mediated eukaryotic translation using single-molecule fluorescence microscopy. RNA. 23(11). 1626–1635. 5 indexed citations
10.
Langley, Richard G., Lawrence F. Eichenfield, Anne W. Lucky, et al.. (2008). Sustained Efficacy and Safety of Pimecrolimus Cream 1% when Used Long‐term (up to 26 Weeks) to Treat Children with Atopic Dermatitis. Pediatric Dermatology. 25(3). 301–307. 29 indexed citations
11.
Murrell, Dédée F., Stefano Calvieri, J.‐P. Ortonne, et al.. (2007). A randomized controlled trial of pimecrolimus cream 1% in adolescents and adults with head and neck atopic dermatitis and intolerant of, or dependent on, topical corticosteroids. British Journal of Dermatology. 157(5). 954–959. 59 indexed citations
12.
Papp, Kim, Thomas Werfel, Regina Fölster‐Holst, et al.. (2005). Long-term control of atopic dermatitis with pimecrolimus cream 1% in infants and young children: A two-year study. Journal of the American Academy of Dermatology. 52(2). 240–246. 84 indexed citations
13.
Papp, Kim, Kristine Breuer, Michael Meurer, et al.. (2005). Long-term treatment of atopic dermatitis with pimecrolimus cream 1% in infants does not interfere with the development of protective antibodies after vaccination. Journal of the American Academy of Dermatology. 52(2). 247–253. 62 indexed citations
14.
Paul, C., Michael J. Cork, Ana B. Rossi, et al.. (2005). Safety and Tolerability of 1% Pimecrolimus Cream Among Infants: Experience With 1133 Patients Treated for Up to 2 Years. PEDIATRICS. 117(1). e118–e128. 85 indexed citations
15.
Papp, Kim, Doris Staab, John Harper, et al.. (2004). Effect of pimecrolimus cream 1% on the long‐term course of pediatric atopic dermatitis. International Journal of Dermatology. 43(12). 978–983. 29 indexed citations
16.
Eichenfield, Lawrence F., Anne W. Lucky, Richard G. Langley, et al.. (2004). Use of pimecrolimus cream 1% (Elidel®) in the treatment of atopic dermatitis in infants and children: the effects of ethnic origin and baseline disease severity on treatment outcome. International Journal of Dermatology. 44(1). 70–75. 34 indexed citations
17.
Barbier, Nathalie, C. Paul, Thomas A. Luger, et al.. (2004). Validation of the Eczema Area and Severity Index for atopic dermatitis in a cohort of 1550 patients from the pimecrolimus cream 1% randomized controlled clinical trials programme. British Journal of Dermatology. 150(1). 96–102. 121 indexed citations
18.
Luger, TA, M. Lahfa, Regina Fölster‐Holst, et al.. (2004). Long‐term safety and tolerability of pimecrolimus cream 1% and topical corticosteroids in adults with moderate to severe atopic dermatitis. Journal of Dermatological Treatment. 15(3). 169–178. 90 indexed citations
19.
Kapp, Alexander, Kim Papp, Ann Bingham, et al.. (2002). Long-term management of atopic dermatitis in infants with topical pimecrolimus, a nonsteroid anti-inflammatory drug. Journal of Allergy and Clinical Immunology. 110(2). 277–284. 199 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Eileen Jaracz Breakdown of academic impact, for papers by May E. Venturanza Breakdown of academic impact, for papers by Bridget Kaufman Breakdown of academic impact, for papers by Murlidhar Rajagopalan Breakdown of academic impact, for papers by Robin Graham‐Brown Breakdown of academic impact, for papers by Yuka Asai Breakdown of academic impact, for papers by José Carlos Armario Hita Breakdown of academic impact, for papers by Hany Elmaraghy Breakdown of academic impact, for papers by Parbeer Grewal Breakdown of academic impact, for papers by Tuấn Anh Lê
Rankless by CCL
2026